Alzamend Neuro is trading at $1.53, down -6.13%, amid biotech-sector weakness.
- No negative company-specific announcement was identified for August 21, 2026.
- Its latest company update was positive: AL001 neuroimaging data were accepted for presentation at Neuroscience 2026 on August 20, 2026.
- XBI fell 2.47% during regular trading after the sector’s recent rally and profit-taking.